Request Demo

Last update 07 May 2025

Toxic Optic Neuropathy

Last update 07 May 2025

Basic Info

Synonyms

Neuropathy, Toxic Optic, Optic Neuropathy, Toxic, Toxic Optic Neuropathies

+ [9]

Introduction

Damage to the eye or its function (e.g., VISUAL IMPAIRMENT) due to OPTIC NERVE damage secondary to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.

Clinical Trials associated with Toxic Optic Neuropathy

NCT05748561

/ RecruitingPhase 2/3IIT

Effect of Intravenous Methylprednisolone and Intravenous Erythropoietin in Toxic Optic Neuropathies: Randomized Clinical Trial.

The goal of this double-blind prospective randomized clinical trial is to determine if the effect of intravenous erythropoietin is superior to the effect of intravenous methylprednisolone in cases of toxic optic neuropathy 4 weeks after therapeutic intervention.
The main question it aims to answer:
• Is there a difference in the visual recovery of toxic optic neuropathies treated with intravenous methylprednisolone in comparison with those treated with intravenous erythropoietin?

Start Date04 Apr 2022

Sponsor / Collaborator

Asociación Para Evitar la Ceguera En México IAP

CTRI/2021/02/031606

/ RecruitingNot ApplicableIIT

To assess the incidence of Ethambutol induced Optic neuropathy (EtON) and evaluate the role of high dose pulse methylprednisolone (IVMP)in these patients

Start Date28 Feb 2021

Sponsor / Collaborator-

NCT05353413

/ Unknown statusNot ApplicableIIT

Diffusion Weighted Magnetic Resonance Imaging and the Optic Nerve Neuropathy.

The aim of the project is to create a new, non-invasive and safe protocol for the early diagnosis of various types of optic neuropathies with the use of diffusion magnetic resonance imaging

Start Date31 Dec 2019

Sponsor / Collaborator

Uniwersytet Medyczny w Bialymstoku

[+1]

100 Clinical Results associated with Toxic Optic Neuropathy

100 Translational Medicine associated with Toxic Optic Neuropathy

0 Patents (Medical) associated with Toxic Optic Neuropathy

384

Literatures (Medical) associated with Toxic Optic Neuropathy

15 Apr 2025·Canadian journal of ophthalmology. Journal canadien d'ophtalmologie

Toxic ethambuthol-induced optic neuropathy in a patient with OPA1 mutation.

Letter

Author: Meyniel, Claire ; Amati-Bonneau, Patrizia ; Touitou, Valérie ; Reynier, Pascal

04 Mar 2025·Neuro-Ophthalmology

Erythropoietin for the Treatment of Methanol Toxic Optic Neuropathy: Does It Really Work? A Case Series

Article

Author: Mohammedsaleh, Asmaa ; Alharazi, Shaima ; Badeeb, Nooran O. ; M. Sadaga, Nihal ; Hadrawi, Manal ; Hijazi, Hasan

Erythropoietin (EPO) has demonstrated neuroprotective properties and has been used in small case series to treat methanol optic neuropathy. This study aims to evaluate the effectiveness of EPO. This retrospective case series included data from patients diagnosed with methanol optic neuropathy between November 2022 and December 2023 from two centers in Jeddah, Saudi Arabia. Demographic information, time of consumption of methanol to EPO treatment, and other treatments administered were collected. Vision assessment was performed before and after EPO treatment. A total of 8 male patients were included, with an average age of 38.25 ± 7.15 years. The median duration of the follow-up was 66 days, ranging from 13 to 660 days. The means of vision in the logMAR of both eyes before EPO treatment was 1.98 ± 1.08, which changed to 1.87 ± 0.89 after EPO treatment. Patient's presenting vision before EPO treatment is a significant positive predictor for the vision after treatment with coefficient = 0.782 and 95% CI = 0.349, 0.936. Time to EPO treatment was not statistically significant in defining end vision. Treating methanol optic neuropathy is challenging and time sensitive. In this case series, EPO and adjuvant steroids showed variable effects on visual improvement. Although the vision improved after the treatment, these differences were not statistically significant. Repeat EPO did not give better outcomes. Long-term follow-up is needed to determine the overall impact of EPO treatment.

01 Jan 2025·Indian Journal of Tuberculosis

Prospective evaluation of ethambutol toxic optic neuropathy in patients of pulmonary tuberculosis

Article

Author: Gandhi, Pulkit ; Gupta, Arushi ; Sharma, Neharika ; Singh, Devendra Kumar ; Goyal, Jawahar Lal ; Singh, Divya ; Gahlot, Abha

AIMThe aim of the study was to evaluate visual parameters for early detection of ethambutol toxicity to prevent irreversible optic nerve damage.METHODThis cohort study included 50 newly diagnosed cases of pulmonary tuberculosis, i.e. 100 eyes, in people aged 18-72 years, who received ethambutol as part of the antitubercular therapy. Before starting antitubercular treatment, at each monthly visit, ophthalmic examination was done that included best corrected visual acuity, optic disc evaluation, colour vision, contrast sensitivity, pupil cycle time and automated perimetry for a period of six months. Ethambutol was discontinued in patients who showed signs of visual impairment. These patients were observed for another three months for reversibility of toxicity.RESULTSVisual functions were normal in all patients at baseline. Out of 50 patients, 47 didn't show any signs of deterioration in visual functions even after six months of oral administration of ethambutol. However, 3 out of 50 patients, i.e. 6 eyes (6 %), showed signs of toxicity after 4-5 months - LogMAR visual acuity deteriorated from 0.00 to 1.08 (±0.40); mean contrast sensitivity deteriorated from 1.725 (±0.075) to 1.12 (±0.18); mean deviation in visual fields got impaired from -1.37 (±0.15) to -10.93 (±2.66); and colour vision got severely affected. All the affected patients were aged above 65.CONCLUSIONIn the present study, six percent of 50 patients showed ethambutol toxic optic neuropathy. It was concluded that patients should be comprehensively evaluated for visual parameters before starting the ethambutol treatment. They should be closely monitored by an ophthalmologist for visual functions every month to detect ethambutol toxicity at the early reversible stage to prevent irreversible damage to the optic nerve. Patients should be asked to report immediately if they detect any blurring of vision or colour vision abnormality.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Toxic Optic Neuropathy

Basic Info

Related

Analysis